RecruitingNCT04443530
Evaluation of Effectiveness and Safety of Ultimaster™ Tansei™ Stent in Routine Clinical Practice
Evaluation of Effectiveness and Safety of Ultimaster™ Tansei™ Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study
Sponsor
Duk-Woo Park, MD
Enrollment
2,000 participants
Start Date
Sep 17, 2020
Study Type
OBSERVATIONAL
Conditions
Summary
This study is to evaluate the effectiveness and safety of Ultimaster Tansei stent in the "real-world" daily practice.
Eligibility
Min Age: 19 Years
Inclusion Criteria3
- Patients ≥ 19 years old
- Patients receiving Ultimaster™ Tansei™ stents.
- The patient or guardian agrees to the study protocol and the schedule of clinical follow-up and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.
Exclusion Criteria3
- Patients with a mixture of other drug-eluting stents (DESs)
- Terminal illness with life-expectancy ≤1 year.
- Patients with cardiogenic shock
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGUltimaster™ Tansei™ stents
Patients receiving Ultimaster™ Tansei™ stents
Locations(11)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04443530
Related Trials
Trial of Orbital Atherectomy Versus Standard Strategy in Calcified Bifurcation Lesions
NCT067368998 locations
Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventional Drug-eluting Stent-based Strategy in Patients With Long and Diffuse Coronary Artery Disease
NCT067102101 location
Scaffold in Emilia Romagna and in the MAGIC Network
NCT0332796117 locations
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
NCT0542737043 locations
S-FLEX Netherlands Registry: Prospective Evaluation of the Supraflex Family Sirolimus-eluting Coronary Stent System
NCT034439997 locations